Form 8-K - Current report:
SEC Accession No. 0000950170-25-073555
Filing Date
2025-05-16
Accepted
2025-05-16 16:15:09
Documents
14
Period of Report
2025-05-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sndx-20250512.htm   iXBRL 8-K 75212
2 EX-10.1 sndx-ex10_1.htm EX-10.1 249947
3 EX-99.1 sndx-ex99_1.htm EX-99.1 17012
4 GRAPHIC img199102934_0.jpg GRAPHIC 14374
  Complete submission text file 0000950170-25-073555.txt   517609

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndx-20250512.xsd EX-101.SCH 24852
16 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20250512_htm.xml XML 4682
Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37708 | Film No.: 25959426
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)